| Literature DB >> 30143000 |
Jamile Leão Rêgo1, Nadja de Lima Santana1, Paulo Roberto Lima Machado2,1, Marcelo Ribeiro-Alves3, Thiago Gomes de Toledo-Pinto3, Léa Cristina Castellucci4,5,6, Milton Ozório Moraes3.
Abstract
BACKGROUND: The major factors contributing for nerve damage and permanent disabilities in leprosy are type 1 or reversal reactions (RR) and type 2 or erythema nodosum leprosum (ENL). Gene profiling of leprosy reactions have shown that different pathways are activated during the course of reactions, which is consistent with the exacerbated immune response exhibited by these patients.Entities:
Keywords: Leprosy reactions; gene expression; profile; OASL; Parkin; Pro-inflammatory; Type-I IFN
Mesh:
Year: 2018 PMID: 30143000 PMCID: PMC6109344 DOI: 10.1186/s12879-018-3348-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical characteristics of leprosy patients
| A - Characteristics of the samplea | ||||
| N individuals | Age, years | Gender M:F | ||
| Cases / Reaction | 94 | 44.05 (13.31) | 58:36 | |
| Controls / No Reaction | 57 | 45.21 (14.98) | 28:29 | |
| B - Clinical characteristics of the cohorta | ||||
|
|
|
| ||
| Tuberculoid (TT) | 20 | (13) | ||
| Borderline tuberculoid (BT) | 30 | (20) | ||
| Borderline (BB) | 18 | (12) | ||
| Borderline lepromatous (BL) | 17 | (11) | ||
| Lepromatous (LL) | 49 | (32) | ||
| Indeterminate leprosy (I) | 11 | (7) | ||
| Other forms (Neural) | 6 | (4) | ||
|
|
|
| ||
| C - Patients with reaction episodea | ||||
| RR | 50 | (53) | ||
| ENL | 44 | (47) | ||
|
|
|
| ||
| D - Patients without reaction episodea | ||||
| PB | 47 | (82) | ||
| MB | 10 | (18) | ||
|
|
|
| ||
aResults are shown as N(%). Abbreviations: SD Standart deviation, M male, F female, PB paucibacillary, MB multibacillary, RR reversal reaction, ENL erythema nodosum leprosum. Patients were also classified under leprosy clinical spectrum according to Ridley & Jopling [9]
Normalized gene expression values of whole blood leukocytes samples of leprosy patients with reactions (n = 94) and leprosy patients without reactions (n = 57)
| Reaction vs No Reaction | |||
|---|---|---|---|
| Gene | Description | log fold change | |
| CCL2 | C-C Motif Chemokine Ligand 2 | 4.04 | 0.0016 |
| PARK | parkinson protein 2, E3 ubiquitin protein ligase | 3.27 | 0.0036 |
| ALOX5 | Arachidonate 5-Lipoxygenase | 2.99 | 0.0108 |
| TLR7 | Toll Like Receptor 7 | 2.98 | 0.011 |
| LRRK2 | Leucine Rich Repeat Kinase 2 | 3.09 | 0.0161 |
| IFNB | interferon beta 1 | 2.36 | 0.0228 |
| TLR10 | Toll Like Receptor 10 | 3.07 | 0.0236 |
| IL18 | Interleukin 18 | 2.34 | 0.0326 |
| TLR3 | Toll Like Receptor 3 | 2.74 | 0.0338 |
| CLEC5A | C-Type Lectin Domain Containing 5A | 2.81 | 0.0446 |
| RR vs No Reaction | |||
| CCL2 | C-C Motif Chemokine Ligand 2 | 4.31 | 0.0002 |
| TLR7 | Toll Like Receptor 7 | 3.81 | 0.0012 |
| PARK | parkinson protein 2, E3 ubiquitin protein ligase | 3.16 | 0.002 |
| ALOX5 | Arachidonate 5-Lipoxygenase | 3.32 | 0.0044 |
| LRRK2 | Leucine Rich Repeat Kinase 2 | 3.28 | 0.0056 |
| IFNB | interferon beta 1 | 2.64 | 0.0104 |
| TLR10 | Toll Like Receptor 10 | 3.08 | 0.0122 |
| TLR3 | Toll Like Receptor 3 | 3.04 | 0.0122 |
| IL18 | Interleukin 18 | 2.65 | 0.014 |
| OAS1 | 2′-5′-oligoadenylate synthetase 1 | 2.51 | 0.0376 |
| IL15 | Interleukin 15 | 2.42 | 0.0446 |
| ENL vs No Reaction | |||
| PARK | parkinson protein 2, E3 ubiquitin protein ligase | 2.13 | 0.0436 |
| ENL vs RR | |||
| TLR7 | Toll Like Receptor 7 | −2.72 | 0.0214 |
*The genes were defined as differentially expressed by the criterion of p-value adjusted for multiple comparisons. Bayesian statistical analysis used a log fold change cutoff of > 1 and adjusted p value of < 0.05. - Abbreviations: RR reversal reaction, ENL erythema nodosum leprosum
Fig. 1Gene expression of whole blood leukocytes in patients with RR as compared to patients without leprosy reactions. A group of genes differentially expressed in RR samples was identified, consisting of 1 chemokine gene (CCL2 logFC = 4.04), 2 PARK genes (PARK logFC =3.27, LRRK2 logFC =3.09), 1 eicosanoid metabolism gene (ALOX5 logFC =2.99), 4 pattern recognition receptor genes (Toll-like receptors -TLRs: TLR7 logFC =2.98, TLR10 logFC =3.07, TLR3 logFC =2.74, and C-lectin receptors-CLRs: CLEC5A logFC =2.81), 2 cytokine genes (IL18 logFC =2.34, IL15 logFC = 2.42) and 2 type I IFN genes (IFNB logFC =2.36, OAS1 logFC = 2.51)